LB4. Efficacy and Safety of Cefiderocol vs. High-Dose Meropenem in Patients with Nosocomial Pneumonia—Results of a Phase 3, Randomized, Multicenter, Double-Blind, Non-Inferiority Study

BACKGROUND: Cefiderocol (CFDC) is a novel siderophore cephalosporin with activity against a broad range of Gram-negative bacteria. In this study, Day 14 all-cause mortality (ACM) rates were compared between CFDC and meropenem (MEM) in patients with nosocomial Gram-negative pneumonia. METHODS: The st...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: Wunderink, Richard G, Matsunaga, Yuko, Ari, Mari, Ariyasu, Mari, Echols, Roger, Menon, Anju, Den Nagata, Tsutae
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6810733/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz415.2487
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars